Results 321 to 330 of about 5,566,486 (385)
Some of the next articles are maybe not open access.
The American Journal of Medicine, 2021
In 2020, the US Food and Drug Administration approved 53 novel drugs. Thirty-six of the 53 (68%) drugs were reviewed and approved through an expedited review pathway, and 31 of the 53 (58%) were approved for treatment of a rare disease. This review includes a summary of the novel drugs approved by the US Food and Drug Administration in 2020.
Alex M Ebied +2 more
openaire +3 more sources
In 2020, the US Food and Drug Administration approved 53 novel drugs. Thirty-six of the 53 (68%) drugs were reviewed and approved through an expedited review pathway, and 31 of the 53 (58%) were approved for treatment of a rare disease. This review includes a summary of the novel drugs approved by the US Food and Drug Administration in 2020.
Alex M Ebied +2 more
openaire +3 more sources
Flexible Drug Approval Policies
Manufacturing & Service Operations Management, 2018Problem definition: To approve a novel drug therapy, the U.S. Food and Drug Administration (FDA) requires clinical trial evidence demonstrating efficacy with 2.5% statistical significance, although the agency often uses regulatory discretion when ...
Fernanda Bravo +2 more
semanticscholar +1 more source
Drug Approval and Surveillance
International Journal of Gynecology & Obstetrics, 1980ABSTRACTThe author proposes that current regulations governing the licensing of drugs, particularly in the United States, need to be changed and replaced by a system of provisional or conditional licensing and increased postmarketing surveillance of drug use.
openaire +3 more sources
Nature Reviews Drug Discovery, 2018
This corrects the article DOI: 10.1038/nrd.2018.4.
openaire +4 more sources
This corrects the article DOI: 10.1038/nrd.2018.4.
openaire +4 more sources
JAMA Oncology, 2018
Importance Accelerated approval (AA) is a US Food and Drug Administration (FDA) expedited program intended to speed the approval of drugs and biologics that may demonstrate a meaningful advantage over available therapies for diseases that are serious or ...
J. Beaver +11 more
semanticscholar +1 more source
Importance Accelerated approval (AA) is a US Food and Drug Administration (FDA) expedited program intended to speed the approval of drugs and biologics that may demonstrate a meaningful advantage over available therapies for diseases that are serious or ...
J. Beaver +11 more
semanticscholar +1 more source
Drugs approved for small ruminants
Journal of the American Veterinary Medical Association, 2004JAVMA, Vol 224, No. 4, February 15, 2004 F the purpose of this FARAD Digest, small ruminants are considered to include sheep, goats, deer, and camelids. In the United States, the small ruminant population is low, and they are all considered minor species under the Food, Drug, and Cosmetics Act (Table 1).
Jim E. Riviere +4 more
openaire +3 more sources
Characteristics of expedited programmes for cancer drug approval in China
Nature reviews. Drug discovery, 2021Guanqiao Li +4 more
semanticscholar +1 more source
Journal of Clinical Oncology, 2018
Purpose The breakthrough therapy program was established in 2012 to expedite the development and review of new medicines. We evaluated the times to approval, efficacy, and safety of breakthrough-designated versus non-breakthrough-designated cancer drugs ...
T. Hwang +6 more
semanticscholar +1 more source
Purpose The breakthrough therapy program was established in 2012 to expedite the development and review of new medicines. We evaluated the times to approval, efficacy, and safety of breakthrough-designated versus non-breakthrough-designated cancer drugs ...
T. Hwang +6 more
semanticscholar +1 more source
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2019
Historically, patient experience, including symptomatic toxicities, physical function, and disease-related symptoms during treatment or their perspectives on clinical trials, has played a secondary role in cancer drug development. Regulatory criteria for
B. Gyawali +5 more
semanticscholar +1 more source
Historically, patient experience, including symptomatic toxicities, physical function, and disease-related symptoms during treatment or their perspectives on clinical trials, has played a secondary role in cancer drug development. Regulatory criteria for
B. Gyawali +5 more
semanticscholar +1 more source

